PE20181805A1 - Composiciones y anticuerpos anti-tim-3 - Google Patents
Composiciones y anticuerpos anti-tim-3Info
- Publication number
- PE20181805A1 PE20181805A1 PE2018001979A PE2018001979A PE20181805A1 PE 20181805 A1 PE20181805 A1 PE 20181805A1 PE 2018001979 A PE2018001979 A PE 2018001979A PE 2018001979 A PE2018001979 A PE 2018001979A PE 20181805 A1 PE20181805 A1 PE 20181805A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- tim
- cdr
- complementarity
- refers
- Prior art date
Links
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO ANTI-TIM-3 CUYAS REGIONES DETERMINANTES DE LA COMPLEMENTARIEDAD DE CADENA PESADA (H-CDR) 1-3 Y REGIONES DETERMINANTES DE LA COMPLEMENTARIEDAD DE CADENA LIGERA (L-CDR) 1-3 COMPRENDEN LAS SECUENCIAS DE AMINOACIDOS DE LAS SEQ ID NO: 7-12, RESPECTIVAMENTE, Y QUE ADEMAS SU DOMINIO VARIABLE DE CADENA PESADA (VH) COMPRENDE LAS SECUENCIAS DE AMINOACIDOS DE SEQ ID NO: 15 O 3, Y SU DOMINIO VARIABLE DE CADENA LIGERA (VL) COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 4. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE, SIENDO UTIL EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321476P | 2016-04-12 | 2016-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181805A1 true PE20181805A1 (es) | 2018-11-19 |
Family
ID=58547516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001979A PE20181805A1 (es) | 2016-04-12 | 2017-04-11 | Composiciones y anticuerpos anti-tim-3 |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US11390674B2 (es) |
| EP (2) | EP3443009B1 (es) |
| JP (2) | JP7123804B2 (es) |
| KR (1) | KR102473028B1 (es) |
| CN (2) | CN116693685A (es) |
| AU (1) | AU2017251250B2 (es) |
| BR (1) | BR112018070919A2 (es) |
| CA (1) | CA3020647A1 (es) |
| CL (1) | CL2018002878A1 (es) |
| CO (1) | CO2018010458A2 (es) |
| CY (1) | CY1125440T1 (es) |
| DK (1) | DK3443009T3 (es) |
| EA (1) | EA039020B1 (es) |
| ES (1) | ES2900381T3 (es) |
| HR (1) | HRP20211820T1 (es) |
| HU (1) | HUE056677T2 (es) |
| IL (1) | IL262176B2 (es) |
| LT (1) | LT3443009T (es) |
| MA (1) | MA44659B1 (es) |
| MD (1) | MD3443009T2 (es) |
| MX (1) | MX2018012076A (es) |
| MY (1) | MY199098A (es) |
| PE (1) | PE20181805A1 (es) |
| PH (1) | PH12018502112B1 (es) |
| PL (1) | PL3443009T3 (es) |
| PT (1) | PT3443009T (es) |
| RS (1) | RS62736B1 (es) |
| SA (1) | SA518400222B1 (es) |
| SG (2) | SG10201912937SA (es) |
| SI (1) | SI3443009T1 (es) |
| TN (1) | TN2018000333A1 (es) |
| TW (1) | TWI752950B (es) |
| UA (1) | UA126854C2 (es) |
| WO (1) | WO2017178493A1 (es) |
| ZA (1) | ZA201806429B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2980390A1 (en) | 2015-03-23 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
| EP4512829A3 (en) | 2016-07-14 | 2025-06-11 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| KR102737715B1 (ko) | 2017-04-05 | 2024-12-03 | 르 라보레또레 쎄르비에르 | Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법 |
| EP3676616A1 (en) | 2017-08-28 | 2020-07-08 | Bristol-Myers Squibb Company | Tim-3 antagonists for the treatment and diagnosis of cancers |
| CN120192415A (zh) * | 2018-01-12 | 2025-06-24 | 百时美施贵宝公司 | 抗tim3抗体及其用途 |
| US12202894B2 (en) | 2018-03-20 | 2025-01-21 | WuXi Biologics Ireland Limited | Anti-TIM-3 antibodies |
| TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
| CN111989341B (zh) * | 2018-04-12 | 2023-06-02 | 南京维立志博生物科技有限公司 | 结合tim-3的抗体及其用途 |
| EP3785732A4 (en) * | 2018-04-24 | 2022-02-23 | Ampsource Biopharma Shanghai Inc. | Antibody against tim-3 and application thereof |
| CN118667019A (zh) * | 2018-08-21 | 2024-09-20 | 阿尔伯特爱因斯坦医学院 | 针对人tim-3的单克隆抗体 |
| CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
| BR112021007968A2 (pt) | 2018-12-19 | 2021-09-08 | Bayer Aktiengesellschaft | Combinação farmacêutica de anticorpos anti-ceacam6 e tim3 |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| US20220233691A1 (en) | 2019-05-30 | 2022-07-28 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
| JP2022548627A (ja) * | 2019-09-16 | 2022-11-21 | ノバルティス アーゲー | 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用 |
| KR102572804B1 (ko) * | 2020-02-25 | 2023-08-31 | 국립암센터 | CD11b+ 세포에서 TIM-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법 |
| US11807688B2 (en) * | 2020-02-28 | 2023-11-07 | Les Laboratoires Servier | Anti-AXL antibodies and compositions |
| CN114057874B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| CN113214396B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 |
| CN116438199A (zh) | 2020-08-31 | 2023-07-14 | 百时美施贵宝公司 | 细胞定位特征和免疫疗法 |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| PL4267105T3 (pl) | 2020-12-28 | 2025-06-30 | Bristol-Myers Squibb Company | Kompozycje przeciwciał i metody ich stosowania |
| WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| WO2022223048A1 (en) | 2021-04-23 | 2022-10-27 | Suzhou Neologics Bioscience Co. , Ltd. | Tim-3-targetting antibodies and uses thereof |
| AR126001A1 (es) * | 2021-06-01 | 2023-08-30 | Symphogen As | Anticuerpos y composiciones anti-nkg2a |
| US20240391997A1 (en) * | 2021-07-16 | 2024-11-28 | Brightpath Biotherapeutics Co., Ltd. | Anti-tim-3 antigen antibody or antibody derivative, and use thereof |
| IL310773A (en) | 2021-09-02 | 2024-04-01 | Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts | Anti-CECAM6 antibodies with reduced side effects |
| WO2023031397A1 (en) | 2021-09-03 | 2023-03-09 | Oncoone Research & Development Gmbh | IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| IL317319A (en) | 2022-06-02 | 2025-01-01 | Bristol Myers Squibb Co | Antibody compounds and methods of using them |
| WO2024224323A1 (en) | 2023-04-24 | 2024-10-31 | King Abdullah University Of Science Of Technology | Compositions, systems and methods for multiplex detection of target biomarkers in a sample |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN118373913B (zh) * | 2024-05-08 | 2024-11-01 | 上海百英生物科技股份有限公司 | 一种抗人Tim-3单克隆抗体及其制备方法 |
| CN118165111B (zh) * | 2024-05-15 | 2024-08-13 | 中国人民解放军军事科学院军事医学研究院 | 针对Tim-3的抗体 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| AU584417B2 (en) | 1985-04-01 | 1989-05-25 | Lonza Group Ag | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| WO2009097394A2 (en) | 2008-01-29 | 2009-08-06 | The Brigham And Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| JP5569946B2 (ja) | 2009-01-26 | 2014-08-13 | 国立大学法人 岡山大学 | 免疫抑制剤および自己免疫疾患の予防および治療剤 |
| EP2417984B1 (en) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
| TR201807750T4 (tr) * | 2010-06-11 | 2018-06-21 | Kyowa Hakko Kirin Co Ltd | Anti-TIM-3 antikoru. |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| WO2013006490A2 (en) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CN103936853B (zh) | 2014-01-26 | 2016-08-17 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测tim-3试剂盒及其使用方法 |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| WO2015136541A2 (en) | 2014-03-12 | 2015-09-17 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| ES2851451T3 (es) | 2014-05-13 | 2021-09-07 | Bavarian Nordic As | Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3 |
| WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| WO2016144803A2 (en) * | 2015-03-06 | 2016-09-15 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind tim3 |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| US11014983B2 (en) | 2015-08-20 | 2021-05-25 | Sutro Biopharma, Inc. | Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies |
| HUE055407T2 (hu) | 2015-10-02 | 2021-11-29 | Hoffmann La Roche | PD1-re és TIM3-ra specifikus bispecifikus antitestek |
| EP4512829A3 (en) | 2016-07-14 | 2025-06-11 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| JOP20190133A1 (ar) | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
| KR102737715B1 (ko) | 2017-04-05 | 2024-12-03 | 르 라보레또레 쎄르비에르 | Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법 |
| JOP20190222A1 (ar) | 2017-04-11 | 2019-09-24 | Zymeworks Inc | الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3 |
-
2017
- 2017-04-11 SI SI201731008T patent/SI3443009T1/sl unknown
- 2017-04-11 MA MA44659A patent/MA44659B1/fr unknown
- 2017-04-11 JP JP2018553410A patent/JP7123804B2/ja active Active
- 2017-04-11 BR BR112018070919A patent/BR112018070919A2/pt active Search and Examination
- 2017-04-11 EA EA201892294A patent/EA039020B1/ru unknown
- 2017-04-11 MX MX2018012076A patent/MX2018012076A/es unknown
- 2017-04-11 US US16/093,024 patent/US11390674B2/en active Active
- 2017-04-11 SG SG10201912937SA patent/SG10201912937SA/en unknown
- 2017-04-11 CA CA3020647A patent/CA3020647A1/en active Pending
- 2017-04-11 HR HRP20211820TT patent/HRP20211820T1/hr unknown
- 2017-04-11 HU HUE17717393A patent/HUE056677T2/hu unknown
- 2017-04-11 SG SG11201808724SA patent/SG11201808724SA/en unknown
- 2017-04-11 UA UAA201811058A patent/UA126854C2/uk unknown
- 2017-04-11 CN CN202310660864.5A patent/CN116693685A/zh active Pending
- 2017-04-11 PT PT177173937T patent/PT3443009T/pt unknown
- 2017-04-11 LT LTEPPCT/EP2017/058696T patent/LT3443009T/lt unknown
- 2017-04-11 AU AU2017251250A patent/AU2017251250B2/en active Active
- 2017-04-11 MY MYPI2018703580A patent/MY199098A/en unknown
- 2017-04-11 ES ES17717393T patent/ES2900381T3/es active Active
- 2017-04-11 MD MDE20190216T patent/MD3443009T2/ro unknown
- 2017-04-11 EP EP17717393.7A patent/EP3443009B1/en active Active
- 2017-04-11 WO PCT/EP2017/058696 patent/WO2017178493A1/en not_active Ceased
- 2017-04-11 DK DK17717393.7T patent/DK3443009T3/da active
- 2017-04-11 PE PE2018001979A patent/PE20181805A1/es unknown
- 2017-04-11 CN CN201780023412.9A patent/CN109451741B/zh active Active
- 2017-04-11 RS RS20211517A patent/RS62736B1/sr unknown
- 2017-04-11 PH PH1/2018/502112A patent/PH12018502112B1/en unknown
- 2017-04-11 IL IL262176A patent/IL262176B2/en unknown
- 2017-04-11 TW TW106112034A patent/TWI752950B/zh active
- 2017-04-11 TN TNP/2018/000333A patent/TN2018000333A1/en unknown
- 2017-04-11 KR KR1020187032586A patent/KR102473028B1/ko active Active
- 2017-04-11 PL PL17717393T patent/PL3443009T3/pl unknown
- 2017-04-11 EP EP21194637.1A patent/EP3978531A1/en active Pending
-
2018
- 2018-09-27 ZA ZA2018/06429A patent/ZA201806429B/en unknown
- 2018-09-28 CO CONC2018/0010458A patent/CO2018010458A2/es unknown
- 2018-10-09 CL CL2018002878A patent/CL2018002878A1/es unknown
- 2018-10-11 SA SA518400222A patent/SA518400222B1/ar unknown
-
2021
- 2021-12-08 CY CY20211101076T patent/CY1125440T1/el unknown
-
2022
- 2022-05-11 US US17/741,967 patent/US20230105714A1/en active Pending
- 2022-08-10 JP JP2022128330A patent/JP2022172142A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| PE20161390A1 (es) | Anticuerpos multiespecificos | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| CL2018000108A1 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| BR112019011988A2 (pt) | anticorpo anti-cd73 humana | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20211291A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20171060A1 (es) | Receptores quimericos de antigeno anti-cldn y metodos de uso | |
| EA201600277A1 (ru) | Высокоаффиные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 |